Accelerating the development and manufacturing of innovative therapies to bring more treatments to more patients.
Pioneering Solutions that turn Hope into Reality
Our values are found in our origin story.
The name “Andelyn” is a hybrid of two gene therapy pioneers who participated in pivotal Phase I clinical trials at Nationwide Children’s Hospital. Andrew received the first U.S. investigational gene therapy for Duchenne muscular dystrophy in 2006. Evelyn received experimental gene therapy for spinal muscular atrophy in 2015. “Andelyn” combines their names, representing all the families who have courageously participated in the research that make today’s gene therapies possible. Learn more.
Painstakingly consistent quality. Peerless compliance with national and international regulations. We-wrote-the-manual expertise. These qualities converge to make Andelyn Biosciences a highly reliable, highly accountable partner.
Providing clients with a consistent quality product. Offering patients life-altering therapies. Our leading-edge technologies help you advance the field of gene and cell-based therapies. Our forward-thinking business model allows us – and you – support the future of child health research.
Andelyn Biosciences is a partner to any organization working to improve human health, with scalable flexibility to adapt to our clients’ needs. A client partner might be a patient foundation searching for a cure. A Fortune 100 company starting Phase 3 trials. A university proposing an IND. Our state-of-the-art cGMP manufacturing facility – opening in 2023 – is capable of early stage development through commercial scale production.
Through our mission, vision and values, Andelyn Biosciences is a company driven to do the right thing for our clients and the patients they serve.